cisapride (Propulsid)

From Aaushi
Jump to navigation Jump to search

Introduction

Tradename: Propulsid. Cisapride withdrawn from US market 7/14/2000. Available only through a limited access program for specific conditions, including:

Indications

Contraindications

pregnancy category = c

safety in lactation = ?

Dosage

  • 10-20 mg PO before meals & QHS
  • daily dosage should be halved in patients with hepatic &/or renal impairment.

Tabs: 10 & 20 mg.

Pharmacokinetics

elimination via liver

elimination via kidney

1/2life = 6-12 hours

protein binding = 98 %

Adverse effects

Drug interactions

Mechanism of action

More general terms

Additional terms

References

  1. The Pharmacological Basis of Therapeutics, 9th ed. Gilman et al, eds. Permagon Press/McGraw Hill, 1996
  2. Physician's Desk Reference (PDR) 51st edition, Medical Economics, 1997
  3. Drug Information & Medication Formulary, Veterans Affairs, Central California Health Care System, 1st ed., Ravnan et al eds, 1998 - not on National VA formulary
  4. Kaiser Permanente Northern California Regional Drug Formulary, 1998 (withdrawn 3/2000)
  5. Prescriber's Letter 7(2):12, Feb. 2000
  6. Formulary Update, Kaiser Permanente Northern California, summer, 2000
  7. Prescriber's Letter 13(3): 2006 Cytochrome P450 drug interactions Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=220233&pb=PRL (subscription needed) http://www.prescribersletter.com
  8. Federal Drug Administration http://www.fda.gov/medwatch/safety/2000/propul1.htm (877) 795-4247

Database